CG Oncology reported a quarterly loss of $0.71 per share, wider than the Zacks Consensus Estimate loss of $0.58 and worse than the $0.45 loss per share a year ago. The miss versus expectations suggests weaker-than-anticipated profitability trends, though the article provides no revenue or guidance details. The update is likely to pressure the stock modestly.
CG Oncology reported a quarterly loss of $0.71 per share, wider than the Zacks Consensus Estimate loss of $0.58 and worse than the $0.45 loss per share a year ago. The miss versus expectations suggests weaker-than-anticipated profitability trends, though the article provides no revenue or guidance details. The update is likely to pressure the stock modestly.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately negative
Sentiment Score
-0.32
Ticker Sentiment
